top of page
    • 6 days ago

Spinal Cord Injury Investor Symposium: The CEO of Axonis Therapeutics discusses the importance of KCC2 inhibition in CNS disorders

Joanna Stanicka describes how Axonis is developing a small molecule that is KCC2-potentiating, with the idea to restore the role that KCC2 inhibition plays in neuronal function.



Join the BiotechTV mailing list

Thanks for subscribing!

Follow BiotechTV

  • Twitter
  • LinkedIn
  • Facebook
  • TikTok
  • Instagram

@BiotechTVHQ

BiotechTV

BiotechTVHQ

@BiotechTV

@BiotechTVHQ

Also look for unique social pages for BiotechTV U.

Sponsor Spotlight

Theragent_Logo-Landscape_red-small.png

Theragent is an advanced therapeutics Contract Development Manufacturing Organization in Arcadia, CA, focused on novel cell and gene therapies for the treatment of cancer and rare diseases. The company’s innovative cGMP facility offers comprehensive end-to-end manufacturing and in-house testing capabilities for clinical and commercial purposes. 

Visit Theragent

bottom of page